Guersenfinal

Information about Guersenfinal

Published on April 17, 2008

Author: WoodRock

Source: authorstream.com

Content

An Overview of Pharmaceutical Pricing in the European Community:  An Overview of Pharmaceutical Pricing in the European Community Summit: Washington D.C. December 5th, 2003 Global Medical Forum geursen-consulting Robert G. Geursen, Ph.D., M.D. Health Policy Consultant [email protected] www.geursen-consulting.de An Overview of Pharmaceutical Pricing in the European Community:  An Overview of Pharmaceutical Pricing in the European Community Summit: Washington D.C. Global Medical Forum i) Features of the European Health Care Market ii) Purchasing Power and Differential Pricing iii) The Impact of the Euro Zone iv) Approaches to Control Drug Prices in Europe v) Consequences and Outlook World Market for Pharmaceuticals / Sales Index in 2002*:  * Source: IMS Health 2003, ex factory prices World Market for Pharmaceuticals / Sales Index in 2002* Europe - The Common Market for Pharmaceutical Products in 2003:  EU Medicines Evaluation Agency in London since 1995 European Patent Office in Munich since 1977 / SPC introduced in 1991 Directive on European Patent still pending - six Member States have implemented the Bio Patent Directive so far Technical Standards re: GMP, GLP, GCP established „Rational Use“ Directives on Labeling, Packaging and Advertising since 1992 European Monetary Union in twelve countries since 1999 Europe - The Common Market for Pharmaceutical Products in 2003 Special Features of the European Health Care Market:  Special Features of the European Health Care Market Biggest regional market of the world with 380 mill. inhabitants High-quality level of health care and medicines Coverage of total population by compulsory sickness funds or national health services Common principles of market access and technical standards No competition between the systems Pharmaceutical industry regarded as an economic asset (?) The (Un) Common European Health Environment:  Cost-containment bite getting deeper („meeting Maastricht criteria”) Accumulation of controls (measures targeting both supply and demand side) Cross-fertilization among countries: regarding price levels, everybody wants to be the average Growing role of regions in health care provision Industry conceding on different measures in each country The (Un) Common European Health Environment An Overview of Pharmaceutical Pricing in the European Community:  An Overview of Pharmaceutical Pricing in the European Community Summit: Washington D.C. Global Medical Forum i) Features of the European Health Care Market ii) Purchasing Power and Differential Pricing iii) The Impact of the Euro Zone iv) Approaches to Control Drug Prices in Europe v) Consequences and Outlook Slide8:  GDP per capita in standard purchasing power: Average of 200+ Regions = 100 Inner London (GB) 243 Hamburg (D) 186 Brussels (B) 169 Luxembourg (L) 176 Vienna (A) 163 Ionianisia (EL) 56 Anatoliki Makedonia, Thraki (EL) 55 Peloponnisos (EL) 53 Açores (P) 52 Extremadura (E) 50 Ipeiros (EL) 42 EU Poverty and Wealth: Up to 600% Divergence Between Regions in 2001 Source: Eurostat, reported year 1998 Price Variations in the European Union :  Price Variations in the European Union Germany France UK Sweden Divergence Victorinox Swiss Army Knife No 16795 48.45 58.90 81.35 72.32 68 % Bosch Accumulator Drill PSR 9.6 51.60 77.45 98.68 99.00 92 % Kodak Digital Camera DC5000 806.73 913.30 841.85 926.53 15 % Calvin Klein Fragrance "Eternity" 100ml 39.24 36.28 47.86 54.50 50 % Panasonic CD Player SL/SX 270 91.93 135.90 124.75 130.68 48 % GAP T-Shirt "Big Oxford" 35.29 38.13 49.27 69.52 97 % Salomon Ski Boot Evolution 28,0 274.47 234.62 279.18 315.46 35 % Nike Football "Geo Merlin" 83.21 72.42 83.32 86.00 19 % Public Prices of Selected Branded Goods in € Source: Swedish Ministry of Foreign Affairs, EIU, 2001 Burger Big Mac Price Index – Europe in 2002 :  Burger Big Mac Price Index – Europe in 2002 Segmented Market and Ramsey* Pricing :  Segmented Market and Ramsey* Pricing Where there is a need to recover fixed costs in several markets, all participants can be made better off by price discrimination according to the elasticities between the various markets The mark up over marginal cost in each market should be inversely proportional to the price sensitivity of demand, i.e. willingness to pay Increased access to product spreads burden of fixed costs Approach adopted by enterprises with high sunk costs, e.g. airlines, railways, utility providers * Frank Plumpton Ramsey, UK economist (1903-1930), a contribution to the theory of taxation (1927) Single Price Versus Price Differentiation:  Note: A single price produces much smaller profits (small rectangle) than does price differentiation (large triangle). Single Price Versus Price Differentiation An Overview of Pharmaceutical Pricing in the European Community:  An Overview of Pharmaceutical Pricing in the European Community Summit: Washington D.C. Global Medical Forum i) Features of the European Health Care Market ii) Purchasing Power and Differential Pricing iii) The Impact of the Euro Zone iv) Approaches to Control Drug Prices in Europe v) Consequences and Outlook The Impact of the Euro for European States:  Need for suppliers to innovate and to demonstrate value-for-money The Euro has triggered further tight macroeconomic policies. National budgets constrained by “Maastricht criteria” National policies shaped by fiscal and monetary requirements Economic constraints accelerate debate on structural reforms of social systems Measures to cut government spending Restrictive policies in health financing The Impact of the Euro for European States The Impact of the Euro:  Higher speed of price harmonization within the Euro zone The Euro has not changed the trends towards more centralized pricing and price corridor strategies, but it has accelerated it. Due to the increased price transparency, prices are more visible and comparable to consumers which will intensify competition Within the Euro zone, the exchange risk for parallel trade is gone, encouraging more parallel trade Regarding countries´ pricing strategies, pharmaceutical companies are forced to act more quickly and adopt strategies to optimize their revenues The Impact of the Euro An Overview of Pharmaceutical Pricing in the European Community:  An Overview of Pharmaceutical Pricing in the European Community Summit: Washington D.C. Global Medical Forum i) Features of the European Health Care Market ii) Purchasing Power and Differential Pricing iii) The Impact of the Euro Zone iv) Approaches to Control Drug Prices in Europe v) Consequences and Outlook Most Frequently Used Approaches to Control Prices in Europe:  comparing with the prices of standards or similar products in the same country comparing with the prices of the same product in other countries using direct, indirect and intangible cost savings as a basis for pricing National Price Referencing International Price Referencing Health-economic Data Most Frequently Used Approaches to Control Prices in Europe Principles of Reference Pricing:  Source: Donald Macarthur, July 2000 Group together marketed products that are deemed interchangeable, and then cap reimbursement for all members of the group (or cluster) at some preset amount below the group’s maximum price Patient is required to pay the amount over this reimbursement level if a product that costs more than the reference level is prescribed At least one product in a group is always fully reimbursable and available Principles of Reference Pricing Slide19:  Hypertension One for all - all for one? / Clustering of Beta-blocking Agents: Which Class? Introduction of Reference Pricing in Europe:  Germany 09/1989 complex regression model, includes pack sizes and formulations, since 1996 patented drugs excluded, reestablished in 01/2004 Netherlands 07/1991 product price below average price based on cost per day, includes patented products Sweden 01/1993 price of cheapest generic +10%; replaced in 2002 by generic substitution Denmark 06/1993 average of two cheapest multi-source products Norway 09/1993 lowest price in group + 5%, abolished in 2000, reestablished in 2003 Spain 06/2000 weighted average of 3 cheapest alternatives Belgium 06/2001 300 products; maximum price reduction 16% Italy 09/2001 list of some 4000 products, including patent protected medicines since 01/2003 France 10/2003 29 substances with a generic substitution rate of 10-45% in 04/2003, clustered into 72 groups Introduction of Reference Pricing in Europe Slide21:  Germany - Drug Market Structure and Market Trends First half-year, ** 1995 to 2001 ex-factory prices; from 2002 pharmacy sales prices Source: GKV-Arzneimittelindex (until 1994), IMS Health (from 1995) In 1993: 5 % price cut; until 1997: price freeze for drugs not under reference pricing; until 2000: global budget caps for outpatient prescription drugs replaced in 2001 by physician-specific budgets Pharmaceuticals – Which Single Price?:  A single price to the manufacturer? A single price to the health insurance funds? Reimbursement policy Co-payment rate A single price to the consumer? Variable share of out-of-pocket payment Pharmaceuticals – Which Single Price? Drug Cost Containment Measures since 1993: Predominance on Pricing:  Source: EFPIA, 2002 Drug Cost Containment Measures since 1993: Predominance on Pricing Slide24:  Pricing in Europe: International Referencing EU - External Price Comparisons are Widespread:  € EU - External Price Comparisons are Widespread European Pharma Price Index Consequences:  Price convergence in Europe over the last 15 years driven by cost containment measures and international referencing Pricing and launch sequence decisions drive the average value for new products European Pharma Price Index Consequences An Overview of Pharmaceutical Pricing in the European Community:  An Overview of Pharmaceutical Pricing in the European Community Summit: Washington D.C. Global Medical Forum i) Features of the European Health Care Market ii) Purchasing Power and Differential Pricing iii) The Impact of the Euro Zone iv) Approaches to Control Drug Prices in Europe v) Consequences and Outlook Slide28:  comparing with the prices of gold standards in the same country comparing with the prices of the same product in other countries use direct, indirect and intangible cost savings as a basis for pricing Carefully select the comparators in clinical studies to show “superiority” for … Carefully plan the launch sequence to establish the best “price sequence” for … Prepare health economic arguments on time for price negotiations, to … Source: Simon · Kucher & Partners National Price Referencing International Price Referencing Health-economic Data Responding to Most Frequent Approaches of Price Controls Determining the Price of a New Medicine The Past:  Determining the Price of a New Medicine The Past Determining the Price of a New Medicine The Future:  Determining the Price of a New Medicine The Future Challenges re: Pharmaceutical Pricing and Reimbursement in Europe:  Challenges re: Pharmaceutical Pricing and Reimbursement in Europe Pricing and reimbursement systems will develop into even more regulated schemes with negotiations replacing market forces. Countries will not primarily be led by medical necessity but by budget constraints. Evidence based medicine related decisions will finally prevail. Relationship management will join marketing acumen as the driving power for market success. For pharmaceutical manufacturers stronger focus on patients will be necessary to complement activities targeted at physicians and health authorities / payers. Knowledge and understanding of all stakeholders will become crucial. Future Pharmaceutical Pricing and Reimbursement in Europe:  Market pricing will be replaced by price negotiations or by price referencing, be it internal or external. Treatment guidelines will play a more prominent role in the selection of drugs. Patients become more involved, both as payers and as decision makers. Relationship management and negotiations skills will be key success factors. Early planning re: indication sequence, clinical trial program, health economic data will become essential for price justification. Life cycle management will become equally important to launch price setting for fully exploiting the revenue potential of new products. Price premiums will still be possible, however, only for truly superior products. Comprehensive deals, e.g. disease management programs, will be the trend . Future Pharmaceutical Pricing and Reimbursement in Europe

Related presentations


Other presentations created by WoodRock

VoIP endfassung
18. 06. 2007
0 views

VoIP endfassung

Lone Wolf Presentation
22. 04. 2008
0 views

Lone Wolf Presentation

10 bridge
16. 04. 2008
0 views

10 bridge

Reveiwfinal spring
14. 04. 2008
0 views

Reveiwfinal spring

ch03 edit
13. 04. 2008
0 views

ch03 edit

Howcroft CME
10. 04. 2008
0 views

Howcroft CME

ARPA07distribute
09. 04. 2008
0 views

ARPA07distribute

PowerPoint Presentation 2007
07. 04. 2008
0 views

PowerPoint Presentation 2007

Central Asia short
30. 03. 2008
0 views

Central Asia short

APALSAGeneralMeeting
27. 03. 2008
0 views

APALSAGeneralMeeting

elements compounds mixtures
04. 01. 2008
0 views

elements compounds mixtures

Moodle for english teachers
27. 06. 2007
0 views

Moodle for english teachers

YagerDOE2005
17. 09. 2007
0 views

YagerDOE2005

JESSICA2 HKJU Dec 18 2002
17. 09. 2007
0 views

JESSICA2 HKJU Dec 18 2002

wipo smes del 07 www 76775
24. 09. 2007
0 views

wipo smes del 07 www 76775

LDAP Integration
24. 09. 2007
0 views

LDAP Integration

SAR presentation Final
24. 09. 2007
0 views

SAR presentation Final

Politics ml Z
02. 10. 2007
0 views

Politics ml Z

sparkles
04. 10. 2007
0 views

sparkles

Extreme Makeover
17. 09. 2007
0 views

Extreme Makeover

current status ebxml cppa tc
29. 10. 2007
0 views

current status ebxml cppa tc

ast201 2007 lect11
28. 11. 2007
0 views

ast201 2007 lect11

judicial
28. 08. 2007
0 views

judicial

Laptop Security
28. 08. 2007
0 views

Laptop Security

hammer fatriv
28. 08. 2007
0 views

hammer fatriv

Air Monitoring
23. 10. 2007
0 views

Air Monitoring

CONFINED
07. 11. 2007
0 views

CONFINED

Kansas GRB 5
15. 11. 2007
0 views

Kansas GRB 5

ATS
16. 11. 2007
0 views

ATS

Lecture 4 Bioterrorism Dunne
17. 11. 2007
0 views

Lecture 4 Bioterrorism Dunne

wieser sybase
20. 11. 2007
0 views

wieser sybase

rushdie
21. 11. 2007
0 views

rushdie

Napoleon I
26. 11. 2007
0 views

Napoleon I

SonnetOL
11. 08. 2007
0 views

SonnetOL

Steve Lafferty optimized
11. 08. 2007
0 views

Steve Lafferty optimized

Tibetian test 2
11. 08. 2007
0 views

Tibetian test 2

Plumbing an Information Space
02. 01. 2008
0 views

Plumbing an Information Space

Tree of Life 3 11 03
11. 08. 2007
0 views

Tree of Life 3 11 03

savas dangerous offenders
11. 08. 2007
0 views

savas dangerous offenders

Memory Revisited
12. 10. 2007
0 views

Memory Revisited

Dermatology Revision
05. 01. 2008
0 views

Dermatology Revision

FROM THE DISCOVERY OF HELIX
16. 10. 2007
0 views

FROM THE DISCOVERY OF HELIX

504d AACR poster 2005 cfg
30. 10. 2007
0 views

504d AACR poster 2005 cfg

Zeeberg
17. 09. 2007
0 views

Zeeberg

sweep
11. 08. 2007
0 views

sweep

Industrialization Ideology
26. 10. 2007
0 views

Industrialization Ideology

CS438 08 Bridges
28. 12. 2007
0 views

CS438 08 Bridges

sa advocacy
24. 09. 2007
0 views

sa advocacy

CausalArguments
26. 11. 2007
0 views

CausalArguments

JostDeutschAwards
07. 01. 2008
0 views

JostDeutschAwards

Class24ImlicatureExp
19. 02. 2008
0 views

Class24ImlicatureExp

Lars Nord Presentation at HA2005
08. 10. 2007
0 views

Lars Nord Presentation at HA2005

ConEvals
27. 02. 2008
0 views

ConEvals

moodle themes
27. 06. 2007
0 views

moodle themes

Moodle lokalp
27. 06. 2007
0 views

Moodle lokalp

Moodle na UE final
27. 06. 2007
0 views

Moodle na UE final

SIRESENAC06
06. 03. 2008
0 views

SIRESENAC06

Seance 4 Alissa fr
24. 10. 2007
0 views

Seance 4 Alissa fr

SKita gesture
11. 08. 2007
0 views

SKita gesture

8 lessons learnt from nms
18. 03. 2008
0 views

8 lessons learnt from nms

WORKING IN THE EU INSTITUTIONS
20. 03. 2008
0 views

WORKING IN THE EU INSTITUTIONS

semantic web applications
25. 03. 2008
0 views

semantic web applications

FutureofNews
05. 10. 2007
0 views

FutureofNews

sxu 1 05 06
11. 08. 2007
0 views

sxu 1 05 06

canarias
23. 10. 2007
0 views

canarias

Reintegration ProgramFinal
28. 12. 2007
0 views

Reintegration ProgramFinal

G Abaee
22. 11. 2007
0 views

G Abaee

tromsoe
11. 08. 2007
0 views

tromsoe

glazerbusan
12. 10. 2007
0 views

glazerbusan

Stockholm Tutorial June 2001
12. 03. 2008
0 views

Stockholm Tutorial June 2001

TF Rschede
18. 06. 2007
0 views

TF Rschede

telwisa 5
18. 06. 2007
0 views

telwisa 5

Teitler Framework
18. 06. 2007
0 views

Teitler Framework

STRUMENTI tris DI ATTUAZIONE
18. 06. 2007
0 views

STRUMENTI tris DI ATTUAZIONE

strategic plan
18. 06. 2007
0 views

strategic plan

STEROIDS
18. 06. 2007
0 views

STEROIDS

Slide musso taranto
18. 06. 2007
0 views

Slide musso taranto

V 005 Gierke
18. 06. 2007
0 views

V 005 Gierke

Vorlesung BGB AT 1
18. 06. 2007
0 views

Vorlesung BGB AT 1

violenza
18. 06. 2007
0 views

violenza

Varma
18. 06. 2007
0 views

Varma

usenix
18. 06. 2007
0 views

usenix

unter Mitglieder wenn das geht
18. 06. 2007
0 views

unter Mitglieder wenn das geht

Unterrichtsbeobachtu ng
18. 06. 2007
0 views

Unterrichtsbeobachtu ng

Traechtigkeit
18. 06. 2007
0 views

Traechtigkeit

todoslossantosanual
02. 11. 2007
0 views

todoslossantosanual

vortrag we mu 220602
18. 06. 2007
0 views

vortrag we mu 220602

SOR Legal Updates 2006 141962 7
11. 08. 2007
0 views

SOR Legal Updates 2006 141962 7

Bigwood 1
13. 03. 2008
0 views

Bigwood 1

lrec metadata
14. 11. 2007
0 views

lrec metadata

termininfo D2D Konferenz2006
18. 06. 2007
0 views

termininfo D2D Konferenz2006

3320 l09
17. 09. 2007
0 views

3320 l09

typologie
18. 06. 2007
0 views

typologie

antalya
03. 09. 2007
0 views

antalya

sermonpp thy will be done
11. 08. 2007
0 views

sermonpp thy will be done

gabriel
24. 09. 2007
0 views

gabriel

tack2
24. 09. 2007
0 views

tack2

VORTRAG BW
18. 06. 2007
0 views

VORTRAG BW

The Perils of Childhood Obesity
11. 08. 2007
0 views

The Perils of Childhood Obesity

GT TurkeyCountryPresent ation
23. 10. 2007
0 views

GT TurkeyCountryPresent ation

Open Everything 3 9
01. 10. 2007
0 views

Open Everything 3 9

arnaud
28. 09. 2007
0 views

arnaud

file1180026507
22. 10. 2007
0 views

file1180026507

yasinsky
24. 09. 2007
0 views

yasinsky

healthy body esteem
03. 10. 2007
0 views

healthy body esteem

moodle presentation epfl final
27. 06. 2007
0 views

moodle presentation epfl final

37 Yale SA Program Overview 07
24. 09. 2007
0 views

37 Yale SA Program Overview 07

song slides
11. 08. 2007
0 views

song slides

Stuttgart
18. 06. 2007
0 views

Stuttgart

site wsa
29. 02. 2008
0 views

site wsa

pearson
24. 09. 2007
0 views

pearson

09 s4 fr
11. 03. 2008
0 views

09 s4 fr

EPS
17. 10. 2007
0 views

EPS

OARS CRJ 2006
24. 09. 2007
0 views

OARS CRJ 2006

7Paul Hopkin
11. 12. 2007
0 views

7Paul Hopkin

Sofia 29 09 30 02
23. 11. 2007
0 views

Sofia 29 09 30 02

CSI NetSec2004
29. 10. 2007
0 views

CSI NetSec2004

santTOPch11
11. 08. 2007
0 views

santTOPch11

HumanCapitalFINAL
24. 09. 2007
0 views

HumanCapitalFINAL

Carmelo Polino
22. 10. 2007
0 views

Carmelo Polino

Poeplau ECLOUD07
03. 01. 2008
0 views

Poeplau ECLOUD07

peytonap
17. 09. 2007
0 views

peytonap

BUTE 2005feb Milano COST291
16. 10. 2007
0 views

BUTE 2005feb Milano COST291